

Electronic supplementary information for the manuscript

“Synthesis of different types of alkoxy fullerene derivatives from chlorofullerene C₆₀Cl₆”

*Ekaterina A. Khakina,^a Ol'ga A. Kraevaya,^{a,b} Maria L. Popova,^b Alexander S. Peregudov,^c
Sergey I. Troyanov,^d Alexander V. Chernyak,^a Vyacheslav M. Martynenko,^a Alexander V.
Kulikov,^a Dominique Schols^e and Pavel A. Troshin^{*f,a}*

Table of contents:

Experimental procedures and selected spectroscopic data	4
X-ray crystallography for 3b	13
Fig. S1. UV-VIS spectra of the C ₆₀ Cl ₆ + Bu ₄ Ni+MeOH reaction mixture and solutions of C ₆₀ [OMe] _s H and Bu ₄ Ni ₃ in chlorobenzene.....	14
Fig. S2. HPLC profile of compound 5g	14
Fig. S3. APCI MS spectrum of compound 1a	14
Fig. S4. ¹ H NMR spectrum of compound 1a	15
Fig. S5. ¹³ C NMR spectrum of compound 1a	15
Fig. S6. APCI MS spectrum of compound 1d	15
Fig. S7. ¹ H NMR spectrum of compound 1d	16
Fig. S8. High-field part of the ¹³ C NMR spectrum of compound 1d	16
Fig. S9. Low-field part of the ¹³ C NMR spectrum of compound 1d	16
Fig. S10. H-H COSY NMR spectrum of compound 1d	17
Fig. S11. H-C HSQC NMR spectrum of compound 1d	17
Fig. S12. APCI mass spectrum of compound 2f	18
Fig. S13. ¹ H NMR spectrum of compound 2f	18
Fig. S14. ¹³ C NMR spectrum of compound 2f	18
Fig. S15. H-H COSY NMR spectrum of compound 2f	19
Fig. S16. H-C HSQC NMR spectrum of compound 2f	19
Fig. S17. APCI mass spectrum of compound 2h	19
Fig. S18. ¹ H NMR spectrum of compound 2h	20
Fig. S19. ¹³ C NMR spectrum of compound 2h	20
Fig. S20. H-H COSY NMR spectrum of compound 2h	21
Fig. S21. H-C HSQC NMR spectrum of compound 2h	21
Fig. S22. APCI mass spectrum of compound 2i	22
Fig. S23. ¹ H NMR spectrum of compound 2i	22
Fig. S24. ¹³ C NMR spectrum of compound 2i	22
Fig. S25. H-H COSY NMR spectrum of compound 2i	23
Fig. S26. H-C HSQC NMR spectrum of compound 2i	23
Fig. S27. APCI mass spectrum of compound 2j	24
Fig. S28. ¹ H NMR spectrum of compound 2j	24
Fig. S29. ¹³ C NMR spectrum of compound 2j	24
Fig. S30. H-C HSQC NMR spectrum of compound 2j	25
Fig. S31. ESI MS spectrum of compound 3a	25

Fig. S32. ^1H NMR spectrum of compound 3a	25
Fig. S33. ^{13}C NMR spectrum of compound 3a	26
Fig. S34 ESI MS spectrum of compound 3b	26
Fig. S35 ^1H NMR spectrum of compound 3b	26
Fig. S36. ^{13}C NMR spectrum of compound 3b	27
Fig. S37. APCI mass spectrum of compound 3d	27
Fig. S38. ^1H NMR spectrum of compound 3d	27
Fig. S39. High-field part of the ^{13}C NMR spectrum of compound 3d	28
Fig. S40. Low-field part of the ^{13}C NMR spectrum of compound 3d	28
Fig. S41. H-C HSQC NMR spectrum of compound 3d	28
Fig. S42. ESI mass spectrum of compound 3g	29
Fig. S43. ^1H NMR spectrum of compound 3g	29
Fig. S44. ^{13}C NMR spectrum of compound 3g	29
Fig. S45. H-C HSQC NMR spectrum of compound 3g	30
Fig. S46. APCI mass spectrum of compound 3i	30
Fig. S47 ^1H NMR spectrum of compound 3i	30
Fig. S48 ^{13}C NMR spectrum of compound 3i	31
Fig. S49. H-H COSY NMR spectrum of compound 3i	31
Fig. S50. H-C HSQC NMR spectrum of compound 3i	32
Fig. S51. APCI mass spectrum of compound 3j	32
Fig. S52. ^1H NMR spectrum of compound 3j	32
Fig. S53. ^{13}C NMR spectrum of compound 3j	33
Fig. S54. H-H COSY NMR spectrum of compound 3j (left) and H-C HSQC NMR spectrum of compound 3j (right).....	33
Fig. S55 APCI MS spectrum of compound 4b	33
Fig. S56. ^1H NMR spectrum of compound 4b	34
Fig. S57. ^{13}C NMR spectrum of compound 4b	34
Fig. S58. H-C HSQC NMR spectrum of compound 4b	35
Fig. S59. H-C HMBC NMR spectrum of compound 4b	35
Fig. S60. APCI MS spectrum of compound 4c	36
Fig. S61. ^1H NMR spectrum of compound 4c	36
Fig. S62. ^{13}C NMR spectrum of compound 4c	36
Fig. S63. H-H COSY NMR spectrum of compound 4c	37
Fig. S64. H-C HSQC NMR spectrum of compound 4c	37
Fig. S65. APCI MS spectrum of compound 4i	38
Fig. S66. ^1H NMR spectrum of compound 4i	38
Fig. S67. ^{13}C NMR spectrum of compound 4i	39
Fig. S68. H-C HSQC NMR spectrum of compound 4i	39
Fig. S69. APCI MS spectrum of compound 5c	40
Fig. S70. ^1H NMR spectrum of compound 5c	40
Fig. S71. ^{13}C NMR spectrum of compound 5c	40
Fig. S72. H-H COSY NMR spectrum of compound 5c	41
Fig. S73. H-C HSQC NMR spectrum of compound 5c	41
Fig. S74. APCI MS spectrum of compound 5d	42
Fig. S75. ^1H NMR spectrum of compound 5d	42
Fig. S76. High-field part of the ^{13}C NMR spectrum of compound 5d	42
Fig. S77. Low-field part of the ^{13}C NMR spectrum of compound 5d	43
Fig. S78. APCI MS spectrum of compound 5e	43
Fig. S79. ^1H NMR spectrum of compound 5e	43
Fig. S80. ^{13}C NMR spectrum of compound 5e	44
Fig. S81. APCI MS spectrum of compound 5g	44
Fig. S82. ^1H NMR spectrum of compound 5g	45

Fig. S83. High-field part of the ^{13}C NMR spectrum of compound 5g	45
Fig. S84. Low-field part of the ^{13}C NMR spectrum of compound 5g	46
Fig. S85. H-H COSY NMR spectrum of compound 5g	46
Fig. S86. H-C HSQC NMR spectrum of compound 5g	47
Fig. S87. APCI MS spectrum of compound 5h	47
Fig. S88. ^1H NMR spectrum of compound 5h	47
Fig. S89. ^{13}C NMR spectrum of compound 5h	48
Fig. S90. H-H COSY NMR spectrum of compound 5h	48
Fig. S91. H-C HSQC NMR spectrum of compound 5h	49
Fig. S92. APCI mass spectrum of compound 5i	49
Fig. S93. ^1H NMR spectrum of compound 5i	49
Fig. S94. ^{13}C NMR spectrum of compound 5i	50
Fig. S95. ^1H NMR spectrum of compound 3j-H	50
Fig. S96. ^{13}C NMR spectrum of compound 3j-H	50
Fig. S97. Comparison of parts of ^{13}C NMR spectra of compounds $\text{C}_{60}(\text{OnBu})_5\text{X}$ (X=H (1), Br (2) and Cl (3)).....	51
Fig. S98. Comparison of regions of ^{13}C NMR spectra of compounds $\text{C}_{60}(\text{OEt})_5\text{Br}$ (1) and $\text{C}_{60}(\text{OEt})_4\text{O}$ (2).....	51
Fig. S99. ESR spectrum of the reaction mixture $\text{C}_{60}\text{Cl}_6+\text{DMPO}+\text{MeOH}+[\text{NBu}_4]\text{Br}$ in toluene proving radical nature of the investigated reaction.....	52
Fig. S100. ESR spectrum of the reaction mixture $\text{C}_{60}\text{Cl}_6+\text{DMPO}+\text{MeOH}+\text{NEt}_3$ in toluene proving radical nature of the investigated reaction.....	52
Fig. S101. ESR spectrum of the reaction mixture $\text{C}_{60}\text{Cl}_6+\text{DMPO}+\text{MeOH}+[\text{NBu}_4]\text{I}$ in toluene proving radical nature of the investigated reaction.....	52

Experimental procedures and selected spectroscopic data

Chlorofullerene C₆₀Cl₆ was prepared as described in P. A. Troshin et al., *Fullerenes, Nanotubes, Carbon Nanostruct.*, **2003**, *11*, 165 and stored in dark.

General procedure for the synthesis of alkoxyfullerenes C₆₀(OR)₅H and C₆₀(OR)₅Br using Bu₄NBr as a reagent

Compounds **1a,d**, **2e-f,h-j** and **3a-b,d,g,i-j** were synthesized according to the following procedure. A triple-neck round-bottom 100 mL flask was evacuated and filled with argon three times. Afterwards, 100 mg of C₆₀Cl₆ (0.11 mmol) and 50 mL of dry chlorobenzene were introduced into the flask in a stream of argon. The mixture was stirred magnetically until complete dissolving of C₆₀Cl₆ with the formation of a transparent orange solution and then an appropriate amount of the corresponding alcohol (1.1-110 mmol, 10-1000 eq.) was added in one portion. Afterwards, a solution of the Bu₄NBr (1.1 mmol, 10 eq.) in 30 ml of dry chlorobenzene was added dropwise to the stirred reaction mixture. In order to obtain compounds **1a,d** the reaction mixture was stirred 30 minutes at room temperature and then diluted by toluene and poured on top of a silica gel column. The target products **1a,d** were eluted using toluene-acetonitrile mixtures (97-99%:1-3% v/v). The obtained solutions of **1a,d** were concentrated at the rotary evaporator, washed with hexanes and dried in air. Compounds **1a,d** were obtained as dark-orange powders.

For preparation of compounds **3a-b, d, g, i-j**, the reaction mixture was stirred 1 h at 55°C after addition of Bu₄NBr solution. Then the reaction mixture was concentrated at the rotary evaporator, the residue was dissolved in toluene and poured on the top of a silica gel column. The target products **3a-b, d, g, i-j** were eluted using toluene-acetonitrile mixtures (97-99% : 1-3% v/v). Compounds **3g, i-j** were eluted using toluene-THF mixtures (70-90% : 10-30% v/v). The obtained solutions of **3a-b, d, g, i-j** were concentrated at the rotary evaporator, washed with hexanes and dried in air. Compounds **3a-b, d, g, i-j** were obtained as dark-orange powders.

Compounds **2e-f, h-j** were isolated as byproducts or even the main products in the reactions between C₆₀Cl₆ and the corresponding alcohols under the reaction conditions specified above.

General procedure for the DMSO-promoted synthesis of alkoxyfullerenes C₆₀(OR)₅Br

Compounds **3a-b, d, g, i-j** were also prepared using the DMSO-promoted synthesis according to the following procedure. A corresponding alcohol (1.61 mmol) and 3 ml of dry DMSO were added to the stirred solution of C₆₀Cl₆ (100 mg, 0.11 mmol) in 150 ml of dry chlorobenzene. Afterwards, a solution of the Bu₄NBr (207 mg, 0.6 mmol) in 50 ml of dry chlorobenzene was added dropwise. The reaction mixture was stirred 30 minutes at room temperature and then diluted by hexanes and poured on top of a silica gel column. The target products **3a-b, d, g, i-j** were eluted using toluene-acetonitrile mixtures (98-99% : 1-2% v/v). The obtained solutions were concentrated at the rotary evaporator, the residues were washed with hexanes and dried in air. The target compounds were obtained as dark-orange powders with 53-70% isolated yields.

1a (Yield 45%). ¹H NMR (500 MHz, CDCl₃:CS₂ 1:1, δ, ppm): 3.87 (s, 3H), 3.95 (s, 6H), 3.96 (s, 6H), 4.81 (s, 1H).

¹³C NMR (125 MHz, CDCl₃:CS₂ 1:1, δ, ppm): 55.44 (OCH₃), 55.61 (OCH₃), 55.88 (OCH₃), 59.53 (C_{sp3} fullerene cage-H), 78.13 (C_{sp3} fullerene cage -O), 80.38 (C_{sp3} fullerene cage -O), 82.34 (C_{sp3} fullerene cage -O), 140.47, 140.87, 142.97, 143.00, 143.11, 143.49, 143.53, 143.98, 144.43, 144.63, 145.21, 145.65, 146.08, 146.48, 146.81, 147.19, 147.26, 147.72, 147.92, 148.11, 148.18, 148.25, 148.46, 149.18, 149.34, 149.75, 152.07, 154.01.

APCI MS: m/z=875 ([M-H]⁻).

C₆₅H₁₆O₅ (876.82): calcd. C 89.04, H 1.84; found C 89.29, H 1.84.

1d (Yield 43%). ¹H NMR (600 MHz, CDCl₃, δ, ppm): 0.97-1.06 (m, 15H), 1.47-1.61 (m, 10H), 1.75-1.85 (m, 10H), 4.12 (t, 2H, *J* = 6.4 Hz), 4.16-4.44 (m, 8H), 4.80 (s, 1H).

¹³C NMR (150 MHz, CDCl₃, δ, ppm): 14.00 (CH₃), 14.03 (CH₃), 14.07 (CH₃), 19.47 (CH₂CH₃), 19.51 (CH₂CH₃), 19.54 (CH₂CH₃), 32.23 (OCH₂CH₂), 32.28 (OCH₂CH₂), 32.34 (OCH₂CH₂), 59.49 (C_{sp3} fullerene cage-H), 67.18 (OCH₂), 67.89 (OCH₂), 68.18 (OCH₂), 77.60 (C_{sp3} fullerene cage-O), 79.81 (C_{sp3} fullerene cage-O), 81.78 (C_{sp3} fullerene cage-O), 140.66, 140.81, 142.86, 143.12, 143.35, 143.36, 143.39, 144.05, 144.26, 144.60, 145.25, 145.66, 146.19, 146.55, 146.78, 147.04, 147.15, 147.25, 147.67, 148.07, 148.14, 148.18, 148.57, 148.86, 149.06, 149.22, 152.47, 154.10.

APCI MS: m/z=1086 ([M-H]⁻).

C₈₀H₄₆O₅ (1087.22): calcd. C 88.38, H 4.26; found C 88.15, H 4.27.

2e (Yield 90%). ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.37-1.39 (m, 12H), 4.96-5.04 (m, 2H).

ESI MS: m/z=838 ([M]⁺).

Spectroscopic data for compound **2e** were reported previously [A. Avent, P. R. Birkett, A. Darwish, S. Houlton, R. Taylor, K. S. T. Thomson, X. W. Wei. *J. Chem. Soc. Perkin Trans. 2*, 2001, 782].

2f (Yield 73%). ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 1.18-1.22 (m, 12H), 1.98-2.07 (m, 8H), 4.85 (p, 2H, $J = 5.8$ Hz).

^{13}C NMR (150 MHz, CDCl_3 , δ , ppm): 10.03 ($\underline{\text{C}}\text{H}_3$), 10.06 ($\underline{\text{C}}\text{H}_3$), 28.00 ($\underline{\text{C}}\text{H}_2$), 28.15 ($\underline{\text{C}}\text{H}_2$), 79.35 ($\underline{\text{C}}_{\text{sp}3}$ fullerene cage-O), 79.62 ($\underline{\text{C}}\text{H}$), 138.54, 139.40, 140.50, 141.27, 142.28, 142.31, 143.02, 143.11, 143.17, 143.29, 143.30, 143.32, 143.77, 143.88, 144.22, 144.31, 144.34, 144.48, 145.60, 145.81, 146.53, 146.82, 146.99, 147.38, 147.49, 148.91, 149.32, 150.78.

ESI MS: $m/z=894$ ($[\text{M}]^-$).

2h (Yield 34%). ^1H NMR (500 MHz, CDCl_3 , δ , ppm): 3.46 (s, 6H), 3.68 (dd, 4H, $J = 5.5$; 3.9 Hz), 3.88 (dd, 4H, $J = 5.5$; 3.9 Hz), 4.11 (t, 4H, $J = 4.9$ Hz), 4.78-4.86 (m, 4H).

^{13}C NMR (125 MHz, CDCl_3 , δ , ppm): 59.18 ($\underline{\text{C}}\text{H}_3$), 67.32 ($\underline{\text{C}}\text{H}_2$), 70.86 ($\underline{\text{C}}\text{H}_2$), 70.92 ($\underline{\text{C}}\text{H}_2$), 72.14 ($\underline{\text{C}}\text{H}_2$), 79.75 ($\underline{\text{C}}_{\text{sp}3}$ fullerene cage-O), 138.57, 139.88, 140.73, 141.23, 142.25, 142.32, 142.90, 143.15, 143.27, 143.31, 143.35, 143.39, 143.64, 143.77, 143.80, 144.22, 144.30, 144.45, 144.48, 145.76, 145.87, 146.58, 146.69, 146.88, 146.99, 147.05, 147.40, 148.21, 149.00, 149.62.

ESI MS: $m/z=958$ ($[\text{M}]^-$).

$\text{C}_{70}\text{H}_{22}\text{O}_6$ (958.92): calcd. C 87.68, H 2.31; found C 87.42, H 2.32.

2i (Yield 36%). ^1H NMR (500 MHz, CDCl_3 , δ , ppm): 3.40 (s, 6H), 3.59 (dd, 4H, $J = 5.6$; 3.8 Hz), 3.72 (dd, 4H, $J = 5.6$; 3.8 Hz), 3.77-3.79 (m, 4H), 3.88-3.90 (m, 4H), 4.08-4.10 (t, 4H, $J = 4.8$ Hz), 4.75-4.83 (m, 4H).

^{13}C NMR (125 MHz, CDCl_3 , δ , ppm): 59.13 ($\underline{\text{C}}\text{H}_3$), 67.30 ($\underline{\text{C}}\text{H}_2$), 70.68 ($\underline{\text{C}}\text{H}_2$), 70.81 ($\underline{\text{C}}\text{H}_2$), 70.82 ($\underline{\text{C}}\text{H}_2$), 71.00 ($\underline{\text{C}}\text{H}_2$), 72.03 ($\underline{\text{C}}\text{H}_2$), 79.74 ($\underline{\text{C}}_{\text{sp}3}$ fullerene cage-O), 138.57, 139.87, 140.73, 141.23, 142.25, 142.31, 142.89, 143.12, 143.15, 143.27, 143.30, 143.35, 143.39, 143.63, 143.76, 143.80, 144.22, 144.29, 144.44, 144.48, 145.75, 145.87, 146.58, 146.68, 146.87, 146.97, 147.05, 147.39, 148.22, 148.99, 149.62.

ESI MS: $m/z=1053$ ($[\text{M}+\text{Li}]^+$).

$\text{C}_{74}\text{H}_{30}\text{O}_8$ (1047.03): calcd. C 84.89, H 2.89; found C 84.67, H 2.91.

2j (Yield 21%). ^1H NMR (500 MHz, CDCl_3 , δ , ppm): 1.54 (s, 18H), 2.95-2.98 (t, 4H, $J = 6.4$ Hz), 4.81-4.90 (m, 4H).

^{13}C NMR (125 MHz, CDCl_3 , δ , ppm): 28.27 ($\text{COOC}(\underline{\text{C}}\text{H}_3)_3$), 36.75 ($\underline{\text{C}}\text{H}_2$), 63.70 ($\underline{\text{C}}\text{H}_2$), 79.73 ($\text{COOC}(\underline{\text{C}}\text{H}_3)_3$), 80.92 ($\underline{\text{C}}_{\text{sp}3}$ fullerene cage-O), 138.57, 139.84, 140.72, 141.26, 142.25, 142.31, 142.90, 143.14, 143.29, 143.31, 143.34, 143.38, 143.63, 143.82, 144.23, 144.30, 144.43, 144.49, 145.75, 145.86, 146.58, 146.66, 146.89, 146.96, 147.05, 147.39, 148.26, 148.99, 149.62, 170.54 ($\underline{\text{C}}\text{OO}$).

ESI MS: $m/z=1033$ ($[M+Na]^+$).

3a (Yield 25%). 1H NMR (500 MHz, $CDCl_3$, δ , ppm): 3.94 (s, 3H), 3.98 (s, 6H), 4.06 (s, 6H).

^{13}C NMR (150 MHz, $CDCl_3$, δ , ppm): 55.50 (\underline{CH}_3), 56.00 (\underline{CH}_3), 58.34 (\underline{CH}_3), 65.69 (\underline{C}_{sp3} fullerene cage-Br), 77.57 (\underline{C}_{sp3} fullerene cage-O), 80.05 (\underline{C}_{sp3} fullerene cage-O), 81.51 (\underline{C}_{sp3} fullerene cage-O), 138.02, 142.22, 142.42, 142.60, 142.94, 142.98, 143.35, 143.56, 143.86, 144.37, 144.49, 144.92, 145.02, 145.36, 146.77, 146.95, 147.18, 147.34, 147.35, 147.71, 148.23, 148.33, 148.34, 148.45, 149.02, 149.18, 151.24, 154.65.

ESI MS: $m/z=875$ ($[M-Br]^-$).

$C_{65}H_{15}BrO_5$ (955.72): calcd. C 81.69, H 1.58, Br 8.36; found C 81.47, H 1.59, Br 8.33.

3b (Yield 38%). 1H NMR (600 MHz, $CDCl_3$, δ , ppm): 1.45-1.48 (m, 9H), 1.53 (t, 6H, $J = 7.0$ Hz), 4.22-4.32 (m, 8H), 4.46-4.51 (m, 2H).

^{13}C NMR (150 MHz, $CDCl_3$, δ , ppm): 15.35 (\underline{CH}_3), 15.84 (\underline{CH}_3), 16.08 (\underline{CH}_3), 63.76 (\underline{OCH}_2), 64.24 (\underline{OCH}_2), 66.16 (\underline{C}_{sp3} fullerene cage-Br), 66.95 (\underline{OCH}_2), 79.54 (\underline{C}_{sp3} fullerene cage-O), 81.46 (\underline{C}_{sp3} fullerene cage-O), 138.28, 142.50, 142.67, 142.81, 143.24, 143.47, 143.59, 144.13, 144.36, 144.73, 145.08, 145.26, 145.49, 146.94, 147.32, 147.46, 147.79, 147.81, 148.31, 148.44, 148.56, 148.76, 149.07, 149.21, 151.88, 154.66.

ESI MS: $m/z=945$ ($[M-Br]^-$).

3d (Yield 30%). 1H NMR (600 MHz, $CDCl_3$, δ , ppm): 0.96-1.05 (m, 15H), 1.46-1.63 (m, 10H), 1.78-1.89 (m, 10H), 4.15-4.24 (m, 8H), 4.39-4.43 (m, 2H).

^{13}C NMR (150 MHz, $CDCl_3$, δ , ppm): 13.96 (\underline{CH}_3), 14.06 (\underline{CH}_3), 14.14 (\underline{CH}_3), 19.31 (\underline{CH}_2CH_3), 19.56 (\underline{CH}_2CH_3), 19.58 (\underline{CH}_2CH_3), 31.86 ($\underline{OCH}_2\underline{CH}_2$), 32.28 ($\underline{OCH}_2\underline{CH}_2$), 32.39 ($\underline{OCH}_2\underline{CH}_2$), 66.29 (\underline{C}_{sp3} fullerene cage-Br), 67.88 (\underline{OCH}_2), 68.50 (\underline{OCH}_2), 70.98 (\underline{OCH}_2), 79.57 (\underline{C}_{sp3} fullerene cage-O), 81.35 (\underline{C}_{sp3} fullerene cage-O), 138.34, 142.58, 142.65, 142.87, 143.11, 143.15, 143.47, 143.59, 144.14, 144.36, 144.79, 145.02, 145.26, 145.53, 146.93, 147.32, 147.46, 147.48, 147.79, 148.31, 148.43, 148.53, 148.56, 148.84, 149.05, 149.19, 151.95, 154.80.

APCI MS: $m/z=1086$ ($[M-Br]^-$), 1166 ($[M]^-$), 866 ($[M-3(OnBu)-Br]^-$).

$C_{80}H_{45}BrO_5$ (1166.11): calcd. C 82.40, H 3.89, Br 6.86; found C 82.23, H 3.91, Br 6.84.

3g (Yield 33%). 1H NMR (500 MHz, $CDCl_3:CD_3OD$ 10:1, δ , ppm): 3.40 (s, 3H), 3.44 (s, 6H), 3.47 (s, 6H), 3.75-3.90 (m, 10H), 4.30-4.44 (m, 8H), 4.48-4.56 (m, 2H).

^{13}C NMR (125 MHz, $CDCl_3:CD_3OD$ 10:1, δ , ppm): 58.89 (\underline{OCH}_3), 58.99 (\underline{OCH}_3), 59.17 (\underline{OCH}_3), 65.94 (\underline{C}_{sp3} fullerene cage-Br), 67.38 (\underline{CH}_2), 67.88 (\underline{CH}_2), 69.94 (\underline{CH}_2), 71.49 (\underline{CH}_2), 71.84 (\underline{CH}_2), 71.91 (\underline{CH}_2), 77.28 (\underline{C}_{sp3} fullerene cage-O), 79.51 (\underline{C}_{sp3} fullerene cage-O), 81.48 (\underline{C}_{sp3} fullerene cage-O), 137.90, 142.34, 142.38, 142.66, 143.03, 143.48, 143.63, 143.99, 144.45, 144.71, 145.07, 145.09,

145.40, 146.93, 147.29, 147.32, 147.46, 147.47, 147.81, 148.30, 148.45, 148.57, 148.58, 149.12, 149.27, 151.49, 154.63.

ESI MS: $m/z=1095$ ($[M-Br]^-$).

$C_{75}H_{35}BrO_{10}$ (1175.98): calcd. C 76.60, H 3.00, Br 6.79; found C 76.51, H 3.03, Br 6.77.

3i (Yield 11%). 1H NMR (500 MHz, $CDCl_3$, δ , ppm): 3.36-3.39 (m, 15H), 3.52-3.81 (m, 40H), 3.87-3.98 (m, 10H), 4.33-4.44 (m, 8H), 4.51-4.62 (m, 2H).

^{13}C NMR (125 MHz, $CDCl_3$, δ , ppm): 59.14 (OCH_3), 66.05 (C_{sp^3} fullerene cage-Br), 67.59 ($\underline{CH_2}$), 67.92 ($\underline{CH_2}$), 68.14 ($\underline{CH_2}$), 70.11 ($\underline{CH_2}$), 70.25 ($\underline{CH_2}$), 70.36 ($\underline{CH_2}$), 70.53 ($\underline{CH_2}$), 70.66 ($\underline{CH_2}$), 70.76 ($\underline{CH_2}$), 70.87 ($\underline{CH_2}$), 71.93 ($\underline{CH_2}$), 72.02 ($\underline{CH_2}$), 72.49 ($\underline{CH_2}$), 79.50 (C_{sp^3} fullerene cage-O), 81.54 (C_{sp^3} fullerene cage-O), 137.99, 142.36, 142.42, 142.43, 142.68, 143.03, 143.49, 143.63, 144.01, 144.44, 144.71, 145.05, 145.17, 145.42, 146.94, 146.99, 147.32, 147.46, 147.49, 147.83, 148.34, 148.42, 148.46, 148.59, 149.14, 149.28, 151.56, 154.66.

APCI MS: $m/z=1536$ ($[M-Br]^-$), 1389 ($[M-Br-OR+H_2O]^-$).

3j. 1H NMR (500 MHz, $CDCl_3$, δ , ppm): 1.42 (s, 9H), 1.45-1.46 (m, 36H), 2.73-2.82 (m, 10H), 4.36-4.58 (m, 10H).

^{13}C NMR (125 MHz, $CDCl_3$, δ , ppm): 28.26 ($\underline{CH_3}$), 28.30 ($\underline{CH_3}$), 28.34 ($\underline{CH_3}$), 36.39 ($\underline{CH_2}$), 36.43 ($\underline{CH_2}$), 36.72 ($\underline{CH_2}$), 63.90 ($\underline{CH_2}$), 64.56 ($\underline{CH_2}$), 65.73 (C_{sp^3} fullerene cage-Br), 66.49 ($\underline{CH_2}$), 77.01 (C_{sp^3} fullerene cage-O), 79.52 (C_{sp^3} fullerene cage-O), 80.67 ($\underline{C(CH_3)_3}$), 80.75 ($\underline{C(CH_3)_3}$), 80.78 ($\underline{C(CH_3)_3}$), 81.29 (C_{sp^3} fullerene cage-O), 138.12, 142.55, 142.59, 142.79, 143.00, 143.59, 143.73, 144.07, 144.55, 144.79, 145.11, 145.22, 145.54, 147.01, 147.32, 147.40, 147.56, 147.57, 147.91, 148.42, 148.47, 148.54, 148.65, 149.19, 149.34, 151.68, 154.91, 170.46 (\underline{COO}), 170.50 (\underline{COO}), 170.62 (\underline{COO}).

APCI MS: $m/z=1446$ ($[M-Br]^-$).

$C_{95}H_{65}BrO_{15}$ (1526.43): calcd. C 74.75, H 4.29, Br 5.23; found C 74.73, H 4.30, Br 5.21.

General procedure for the synthesis of epoxide-type alkoxyfullerenes $C_{60}(OR)_4O$

Compounds **4b-c,i** were synthesized according to the following procedure. A triple-neck round-bottom 100 mL flask was evacuated and filled with argon three times. Afterwards, 100 mg of $C_{60}Cl_6$ (0.11 mmol) and 50 mL of toluene were introduced into the flask in a stream of argon. The mixture was stirred magnetically until complete dissolving of $C_{60}Cl_6$ with the formation of transparent orange solution. Afterwards, an excess of the corresponding alcohol (11 mmol, 100 eq.) and 0.1 ml of distilled water were added in one portion. Then a solution of the Bu_4NBr (345 mg, 1.1 mmol) in 30 ml of toluene was added dropwise. The reaction mixture was stirred 12 hours at room temperature and then diluted by toluene and poured on top of a silica gel column.

The target products **4b-c,i** were eluted using toluene-acetonitrile mixtures (97-99% : 1-3% v/v) after elution of corresponding bromides. The obtained solutions of **4b-c,i** were concentrated at the rotary evaporator, washed with hexanes and dried in air. Compounds **4b-c,i** were obtained as dark-orange powders.

4b (Yield 31%). ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.46 (t, 6H, *J* = 7.0 Hz), 1.52 (t, 6H, *J* = 7.0 Hz), 4.23-4.33 (m, 6H), 4.45-4.51 (m, 2H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 15.83 (CH₃), 16.07 (CH₃), 63.81 (CH₂), 64.46 (CH₂), 76.19 (C_{sp3} fullerene cage-O), 76.98 (C_{sp3} fullerene cage-O), 77.24 (C_{sp3} fullerene cage-O), 79.46 (C_{sp3} fullerene cage-O), 137.25, 142.43, 142.69, 142.75, 143.45, 143.59, 143.62, 144.11, 144.39, 144.85, 145.03, 145.26, 145.42, 146.93, 147.28, 147.43, 147.49, 147.77, 148.29, 148.33, 148.43, 148.58, 148.61, 148.68, 149.10, 149.19, 151.55, 154.40.

APCI MS: *m/z*=916 ([M]⁻).

C₆₈H₂₀O₅ (916.88): calcd. C 89.08, H 2.20; found C 88.94, H 2.21.

4c (Yield 17%). ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.09-1.14 (m, 12H), 1.82-1.96 (m, 8H), 4.13-4.22 (m, 6H), 4.35-4.40 (m, 2H).

¹³C NMR (150 MHz, CDCl₃, δ, ppm): 10.90 (CH₃), 11.04 (CH₃), 23.46 (CH₂), 23.63 (CH₂), 69.85 (CH₂), 70.47 (CH₂), 76.17 (C_{sp3} fullerene cage-O), 79.49 (C_{sp3} fullerene cage-O), 137.34, 142.51, 142.73, 142.77, 143.46, 143.60, 143.62, 144.11, 144.39, 144.90, 145.02, 145.25, 145.45, 146.93, 147.28, 147.43, 147.50, 147.77, 148.16, 148.33, 148.43, 148.56, 148.61, 148.71, 149.10, 149.18, 151.64, 154.40.

APCI MS: *m/z*=972 ([M]⁻).

4i (Yield 25%). ¹H NMR (500 MHz, CDCl₃, δ, ppm): 3.37 (s, 12H), 3.55 (dd, 8H, *J* = 5.5; 3.8 Hz), 3.65-3.70 (m, 16H), 3.76-3.78 (m, 8H), 3.89 (dt, 8H, *J* = 9.9; 4.9 Hz), 4.27-4.46 (m, 8H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 59.07 (CH₃), 67.79 (CH₂), 68.66 (CH₂), 70.51 (CH₂), 70.59 (CH₂), 70.68 (CH₂), 70.70 (CH₂), 70.80 (CH₂), 71.97 (CH₂), 76.65 (C_{sp3} fullerene cage-O), 77.24 (C_{sp3} fullerene cage-O), 77.51 (C_{sp3} fullerene cage-O), 81.86 (C_{sp3} fullerene cage-O), 140.44, 142.15, 143.09, 143.20, 143.61, 143.70, 144.37, 144.43, 144.77, 145.17, 145.20, 146.37, 146.47, 146.71, 146.85, 147.05, 147.10, 147.18, 147.22, 147.26, 147.42, 147.73, 148.02, 149.50, 149.66, 150.00, 150.71.

APCI MS: *m/z*=1411 ([M+Na]⁺).

C₈₈H₆₀O₁₇ (1389.41): calcd. C 76.07, H 4.35; found C 76.04, H 4.36.

General procedure for the synthesis of alkoxyfullerenes C₆₀(OR)₅Cl using triethylamine as a base

Compounds **5a-e,g-i** were synthesized according to the following procedure. An excess of the corresponding alcohol (1.1-110 mmol, 10-1000 eq.) and triethylamine (542 mg, 5.36 mmol) were added to the stirred solution of C₆₀Cl₆ (100 mg, 0.11 mmol) in 70 ml of toluene. The reaction mixture was kept under stirring at room temperature for 30 minutes and then concentrated at the rotary evaporator. The residue was dissolved in toluene and poured on top of a silica gel column. The target products **5a-e** were eluted using toluene-acetonitrile mixtures (97-99% : 1-3% v/v). Compounds **5g-i** were eluted using toluene-tetrahydrofuran mixtures (70-90% : 10-30% v/v). The obtained solutions of **5a-e,g-i** were concentrated at the rotary evaporator, washed with hexanes and dried in air. Compounds **5a-e,g-i** were obtained as dark-orange powders with 38-52% yields.

5a. ¹H NMR (600 MHz, bromobenzene-D₅, δ, ppm): 3.83 (s, 6H), 3.86 (s, 3H), 3.94 (s, 6H).

¹³C NMR (150 MHz, bromobenzene-D₅, δ, ppm): 55.44 (CH₃), 55.91 (CH₃), 58.45 (CH₃), 73.90 (C_{sp3} fullerene cage-Cl), 77.64 (C_{sp3} fullerene cage-O), 80.10 (C_{sp3} fullerene cage-O), 82.07 (C_{sp3} fullerene cage-O), 138.08, 142.10, 142.39, 142.64, 143.40, 143.62, 143.77, 144.39, 144.44, 144.49, 145.05, 145.09, 145.36, 146.76, 147.15, 147.31, 147.33, 147.63, 147.73, 148.19, 148.30, 148.38, 148.43, 148.94, 149.07, 151.38, 154.43.

ESI MS: m/z=875 ([M-Cl]⁻).

Spectroscopic data for compound **5a** were reported previously [A. Avent, P. R. Birkett, A. Darwish, S. Houlton, R. Taylor, K. S. T. Thomson, X. W. Wei. *J. Chem. Soc. Perkin Trans. 2*, 2001, 782].

5b. ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.43-1.51 (m, 15H), 4.20-4.43 (m, 10H).

ESI MS: m/z=945 ([M-Cl]⁻).

Spectroscopic data for compound **5b** were reported previously [A. Avent, P. R. Birkett, A. Darwish, S. Houlton, R. Taylor, K. S. T. Thomson, X. W. Wei. *J. Chem. Soc. Perkin Trans. 2*, 2001, 782].

5c. ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.02 (t, 3H, *J* = 7.4 Hz), 1.09-1.13 (m, 12H), 1.81-1.94 (m, 10H), 4.13-4.20 (m, 8H), 4.27-4.31 (m, 2H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 10.59 (CH₃), 10.89 (CH₃), 10.99 (CH₃), 23.30 (CH₂), 23.45 (CH₂), 23.62 (CH₂), 69.94 (CH₂O), 70.27 (CH₂O), 72.97 (CH₂O), 73.86 (C_{sp3} fullerene cage-Cl), 79.41 (C_{sp3} fullerene cage-O), 81.67 (C_{sp3} fullerene cage-O), 138.21, 142.52, 142.57, 142.69, 143.11, 143.51, 143.62, 144.04, 144.36, 144.51, 144.74, 145.15, 145.31, 145.50, 146.98, 147.36, 147.51, 147.79, 148.18, 148.34, 148.45, 148.52, 148.61, 148.82, 149.05, 149.19, 151.85, 154.27.

APCI MS: m/z=1015 ([M-Cl]⁻).

C₇₅H₃₅ClO₅ (1051.53): calcd. C 85.67, H 3.35, Cl 3.37; found C 85.74, H 3.37, Cl 3.35.

5d. ¹H NMR (500 MHz, CDCl₃, δ, ppm): 0.96-1.04 (m, 15H), 1.45-1.63 (m, 10H), 1.78-1.87 (m, 10H), 4.16-4.22 (m, 8H), 4.30-4.35 (m, 2H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 13.97 (CH₃), 14.08 (CH₃), 19.29 (CH₂), 19.54 (CH₂), 32.06 (CH₂), 32.27 (CH₂), 32.40 (CH₂), 67.92 (CH₂O), 68.43 (CH₂O), 71.22 (CH₂O), 73.86 (C_{sp3} fullerene cage-Cl), 79.43 (C_{sp3} fullerene cage-O), 81.68 (C_{sp3} fullerene cage-O), 138.23, 142.54, 142.59, 142.69, 143.52, 143.63, 144.04, 144.38, 144.48, 144.75, 145.15, 145.32, 145.51, 146.98, 147.37, 147.51, 147.53, 147.80, 148.21, 148.34, 148.46, 148.52, 148.62, 148.83, 149.05, 149.19, 151.89, 154.34.

APCI MS: m/z=1085 ([M-Cl]⁻).

C₈₀H₄₅ClO₅ (1121.66): calcd. C 85.66, H 4.04, Cl 3.16; found C 85.50, H 4.05, Cl 3.18.

5e. ¹H NMR (500 MHz, CDCl₃, δ, ppm): 1.44 (dd, 18H, *J* = 11.1; 5.7 Hz), 1.47 (d, 6H, *J* = 6.0 Hz), 1.51 (d, 6H, *J* = 6.1 Hz), 4.69-4.77 (m, 1H), 4.84-4.97 (m, 4H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 24.02 (CH₃), 24.32 (CH₃), 24.43 (CH₃), 24.46 (CH₃), 70.32 (CH), 70.59 (CH), 72.76 (CH), 74.20 (C_{sp3} fullerene cage-Cl), 76.52 (C_{sp3} fullerene cage-O), 78.57 (C_{sp3} fullerene cage-O), 81.86 (C_{sp3} fullerene cage-O), 138.28, 142.60, 142.94, 143.43, 143.53, 143.77, 143.95, 144.29, 144.46, 144.60, 144.86, 145.06, 145.19, 145.41, 146.98, 147.40, 147.55, 147.57, 147.80, 148.31, 148.44, 148.48, 148.50, 148.60, 149.03, 149.15, 152.72, 154.90.

APCI MS: m/z=1015 ([M-Cl]⁻).

C₇₅H₃₅ClO₅ (1051.53): calcd. C 85.67, H 3.35, Cl 3.37; found C 85.58, H 3.39, Cl 3.38.

5g. ¹H NMR (500 MHz, CDCl₃, δ, ppm): 3.41 (s, 3H), 3.46 (s, 6H), 3.47 (s, 6H), 3.76-3.87 (m, 10H), 4.35-4.42 (m, 8H), 4.46-4.49 (m, 2H).

¹³C NMR (125 MHz, CDCl₃, δ, ppm): 59.04 (CH₃), 59.16 (CH₃), 59.21 (CH₃), 67.48 (CH₂O), 67.85 (CH₂O), 70.24 (CH₂O), 71.64 (CH₂O), 71.85 (CH₂O), 71.89 (CH₂O), 73.64 (C_{sp3} fullerene cage-Cl), 76.90 (C_{sp3} fullerene cage-O), 79.36 (C_{sp3} fullerene cage-O), 81.82 (C_{sp3} fullerene cage-O), 137.78, 142.08, 142.35, 142.68, 143.51, 143.66, 143.90, 144.40, 144.45, 144.69, 145.19, 145.39, 146.98, 147.34, 147.50, 147.52, 147.76, 147.81, 148.29, 148.33, 148.47, 148.54, 148.64, 149.11, 149.25, 151.44, 154.14.

APCI MS: m/z=1095 ([M-Cl]⁻).

C₇₅H₃₅ClO₁₀ (1131.53): calcd. C 79.61, H 3.12, Cl 3.13; found C 79.37, H 3.15, Cl 3.12.

5h. ¹H NMR (600 MHz, CDCl₃, δ, ppm): 3.35 (s, 3H), 3.39 (s, 6H), 3.40 (s, 6H), 3.51-3.52 (m, 2H), 3.57-3.59 (m, 8H), 3.69-3.70 (m, 2H), 3.72-3.74 (m, 4H), 3.76-3.78 (m, 4H), 3.85-3.89 (m, 6H), 3.92-3.94 (m, 4H), 4.35-4.41 (m, 8H), 4.45-4.48 (m, 2H).

¹³C NMR (150 MHz, CDCl₃, δ, ppm): 59.05 (CH₃), 59.08 (CH₃), 67.61 (CH₂O), 68.05 (CH₂O), 70.33 (CH₂O), 70.57 (CH₂O), 70.59 (CH₂O), 70.66 (CH₂O), 70.72 (CH₂O), 72.00

($\underline{\text{C}}\text{H}_2\text{O}$), 72.03 ($\underline{\text{C}}\text{H}_2\text{O}$), 72.06 ($\underline{\text{C}}\text{H}_2\text{O}$), 73.66 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-Cl), 76.93 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 79.32 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 81.83 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 137.82, 142.08, 142.36, 142.69, 143.49, 143.64, 143.88, 144.35, 144.42, 144.63, 145.13, 145.19, 145.36, 146.97, 147.34, 147.51, 147.68, 147.81, 148.34, 148.35, 148.46, 148.54, 148.62, 149.11, 149.24, 151.41, 154.13.

APCI MS: $m/z=1373$ ($[\text{M}+\text{Na}]^+$).

5i. ^1H NMR (500 MHz, CDCl_3 , δ , ppm): 3.36 (s, 3H), 3.37-3.38 (m, 12H), 3.50-3.57 (m, 10H), 3.60-3.71 (m, 20H), 3.73-3.79 (m, 10H), 3.83-3.93 (m, 10H), 4.33-4.47 (m, 10H).

^{13}C NMR (125 MHz, CDCl_3 , δ , ppm): 59.06 ($\underline{\text{C}}\text{H}_3$), 67.58 ($\underline{\text{C}}\text{H}_2\text{O}$), 68.02 ($\underline{\text{C}}\text{H}_2\text{O}$), 68.66 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.32 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.55 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.58 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.59 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.63 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.69 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.71 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.77 ($\underline{\text{C}}\text{H}_2\text{O}$), 70.80 ($\underline{\text{C}}\text{H}_2\text{O}$), 71.93 ($\underline{\text{C}}\text{H}_2\text{O}$), 71.96 ($\underline{\text{C}}\text{H}_2\text{O}$), 73.69 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-Cl), 76.93 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 79.32 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 81.87 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 137.81, 142.08, 142.35, 142.69, 143.49, 143.63, 143.88, 144.37, 144.42, 144.63, 145.14, 145.20, 145.36, 146.97, 147.05, 147.34, 147.52, 147.69, 147.81, 148.34, 148.47, 148.55, 148.62, 149.11, 149.25, 151.42, 154.10.

APCI MS: $m/z=1536$ ($[\text{M}-\text{Cl}]^-$).

$\text{C}_{95}\text{H}_{75}\text{ClO}_{20}$ (1572.05): calcd. C 72.58, H 4.81, Cl 2.26; found C 72.49, H 4.85, Cl 2.24.

Synthesis of 3j-H and 3j-K

Compound **3j** (80 mg, 0.05 mmol) was dissolved in 15 mL of CH_2Cl_2 and quenched with trifluoroacetic acid (1 mL) at room temperature. The solvent and excess of CF_3COOH were removed *in vacuo*; the residue was washed with ethyl acetate and then dried in air. Acid **3j-H** was obtained as an orange powder with 98% yield.

Afterwards, **3j-H** (62 mg, 0.05 mmol) was suspended in distilled water (10 mL) and then aqueous solution of K_2CO_3 (17 mg, 0.125 mmol, in 3 mL of water) was added. The obtained solution was filtered *via* syringe PES filter and freeze-dried. Compound **3j-K** was obtained as an orange light powder with virtually quantitative yield.

3j-H. ^1H NMR (500 MHz, acetone- D_6 , δ , ppm): 2.73-2.83 (m, 10H), 4.35-4.60 (m, 10H).

^{13}C NMR (125 MHz, acetone- D_6 , δ , ppm): 34.42 ($\underline{\text{C}}\text{H}_2$), 34.71 ($\underline{\text{C}}\text{H}_2$), 34.80 ($\underline{\text{C}}\text{H}_2$), 64.18 ($\underline{\text{C}}\text{H}_2$), 64.25 ($\underline{\text{C}}\text{H}_2$), 64.32 ($\underline{\text{C}}\text{H}_2$), 64.46 ($\underline{\text{C}}\text{H}_2$), 66.55 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-Br), 76.88 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 79.40 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 79.45 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 81.43 ($\underline{\text{C}}_{\text{sp}^3}$ fullerene cage-O), 137.01, 138.34, 142.50, 142.60, 142.73, 142.74, 142.79, 142.84, 142.92, 143.21, 143.49, 143.51, 143.66, 143.71, 144.12, 144.16, 144.46, 144.51, 144.69, 145.04, 145.18, 145.22, 145.31, 145.36, 145.60, 146.92, 146.96, 147.35, 147.47, 147.49, 147.72, 147.84, 148.32, 148.35, 148.43, 148.46, 148.55, 148.76,

149.02, 149.10, 149.17, 149.23, 149.82, 151.70, 152.00, 154.65, 155.16, 171.68 (COO), 171.99 (COO), 172.12 (COO), 172.19 (COO), 172.63 (COO).

X-ray crystallography for **3b**

Synchrotron X-ray data for single crystal of **3b** ($0.03 \times 0.03 \times 0.01 \text{ mm}^3$) were collected at 100 K on BL14.2 at the BESSY storage ring (Berlin, Germany) using a MAR225 detector, $\lambda = 0.8551 \text{ \AA}$. The structures was solved and anisotropically refined using SHELX package. Absorption correction was not applied. Crystal data for **3b**: $\text{C}_{70}\text{H}_{25}\text{BrO}_5$, $M = 1025.81$, orthorhombic, $Pnma$, $a = 19.765(1)$, $b = 17.350(1)$, $c = 24.003(2) \text{ \AA}$, $V = 8231.2(9) \text{ \AA}^3$, $Z = 8$, $D_{\text{calc}} = 1.656 \text{ g cm}^{-3}$. Anisotropic refinement with 9880 reflections and 866 parameters yielded a conventional $R_1 = 0.104$ for 4087 reflections with $I > 2\sigma(I)$ and $wR_2 = 0.269$ for all reflections. All methylene and methyl hydrogen atoms were placed into geometrically calculated positions and refined in the riding mode. Both $\text{C}_{60}(\text{OC}_2\text{H}_5)\text{Br}$ molecules are located on a mirror plane so that two halves are independent. Due to approximate fivefold symmetry, both molecules are disordered around pseudo C_5 axes with OC_2H_5 groups disordered over two positions each. Br atoms are disordered over 2-4 positions. For more details see CCDC 1496548.




Fig. S1. UV-VIS spectra of the $C_{60}Cl_6 + Bu_4NI + MeOH$ reaction mixture and solutions of $C_{60}[OMe]_5H$ and Bu_4NI_3 in chlorobenzene




Fig. S2. HPLC profile of compound **5g** (Orbit C18 column, 150 x 4.6 mm, acetonitrile/toluene 70/30 v/v, flow rate 1 mL min⁻¹)




Fig. S3. APCI MS spectrum of compound **1a**




Fig. S4. ¹H NMR spectrum of compound **1a** (* denotes signals of the hydrolysis products)




Fig. S5. ¹³C NMR spectrum of compound **1a** (* denotes signals of toluene impurity)




Fig. S6 APCI MS spectrum of compound **1d**




Fig. S7 ¹H NMR spectrum of compound **1d**




Fig. S8. High-field part of the ¹³C NMR spectrum of compound **1d**




Fig. S9. Low-field part of the ¹³C NMR spectrum of compound **1d**




Fig. S10. H-H COSY NMR spectrum of compound **1d**




Fig. S11. H-C HSQC NMR spectrum of compound **1d**




Fig. S12. APCI mass spectrum of compound 2f




Fig. S13. ¹H NMR spectrum of compound 2f




Fig. S14. ¹³C NMR spectrum of compound 2f




Fig. S15. H-H COSY NMR spectrum of compound **2f**




Fig. S16. H-C HSQC NMR spectrum of compound **2f**




Fig. S17. APCI mass spectrum of compound **2h**




Fig. S18 ^1H NMR spectrum of compound **2h**




Fig. S19 ^{13}C NMR spectrum of compound **2h**




Fig. S20 H-H COSY NMR spectrum of compound **2h**




Fig. S21. H-C HSQC NMR spectrum of compound **2h**




Fig. S22. APCI mass spectrum of compound 2i ($[M+Li]^+$)




Fig. S23. ¹H NMR spectrum of compound 2i




Fig. S24. ¹³C NMR spectrum of compound 2i




Fig. S25. H-H COSY NMR spectrum of compound **2i**




Fig. S26. H-C HSQC NMR spectrum of compound **2i**




Fig. S27. APCI mass spectrum of compound 2j ($[M+Na]^+$)




Fig. S28. 1H NMR spectrum of compound 2j




Fig. S29. ^{13}C NMR spectrum of compound 2j




Fig. S30. H-C HSQC NMR spectrum of compound **2j**




Fig. S31. ESI MS spectrum of compound **3a**




Fig. S32. ^1H NMR spectrum of compound **3a**




Fig. S33. ^{13}C NMR spectrum of compound 3a




Fig. S34 ESI MS spectrum of compound 3b




Fig. S35 ^1H NMR spectrum of compound 3b




Fig. S36. ^{13}C NMR spectrum of compound **3b**




Fig. S37. APCI mass spectrum of compound **3d**




Fig. S38. ^1H NMR spectrum of compound **3d** (“*” denotes signals of $\text{C}_{60}(\text{OC}_4\text{H}_9)_2$ impurity)




Fig. S39. High-field part of the ^{13}C NMR spectrum of compound **3d**




Fig. S40. Low-field part of the ^{13}C NMR spectrum of compound **3d**




Fig. S41. H-C HSQC NMR spectrum of compound **3d**




Fig. S42. ESI mass spectrum of compound **3g**




Fig. S43. ¹H NMR spectrum of compound **3g**




Fig. S44. ¹³C NMR spectrum of compound **3g**




Fig. S45. H-C HSQC NMR spectrum of compound **3g**




Fig. S46. APCI mass spectrum of compound **3i**: 1536 ([M-Br]⁻), 1389 ([M-Br-OR+H₂O]⁻)




Fig. S47 ¹H NMR spectrum of compound **3i**




Fig. S48 ^{13}C NMR spectrum of compound **3i**




Fig. S49. H-H COSY NMR spectrum of compound **3i**




Fig. S50. H-C HSQC NMR spectrum of compound **3i**




Fig. S51. APCI mass spectrum of compound **3j** (1446 $[M-Cl]^-$, 1404 $[M-Cl-C(CH_3)_2]^-$, 1317 $[M-Cl-OC_2H_4COOC(CH_3)_3+O]^-$).




Fig. S52. 1H NMR spectrum of compound **3j**




Fig. S53. ^{13}C NMR spectrum of compound **3j**




Fig. S54. H-H COSY NMR spectrum of compound **3j** (left) and H-C HSQC NMR spectrum of compound **3j** (right)




Fig. S55 APCI MS spectrum of compound **4b**




Fig. S56. ¹H NMR spectrum of compound **4b**




Fig. S57. ¹³C NMR spectrum of compound **4b** (* denotes signals of unknown impurity)




Fig. S58. H-C HSQC NMR spectrum of compound **4b**




Fig. S59. H-C HMBC NMR spectrum of compound **4b**




Fig. S60. APCI MS spectrum of compound **4c**




Fig. S61. ¹H NMR spectrum of compound **4c**




Fig. S62. ¹³C NMR spectrum of compound **4c**




Fig. S63. H-H COSY NMR spectrum of compound **4c**




Fig. S64. H-C HSQC NMR spectrum of compound **4c**




Fig. S65. APCI MS spectrum of compound **4i** ($[M+Na]^+$)




Fig. S66. ^1H NMR spectrum of compound **4i**




Fig. S67. ^{13}C NMR spectrum of compound 4i




Fig. S68. H-C HSQC NMR spectrum of compound 4i




Fig. S69. APCI MS spectrum of compound **5c**




Fig. S70. ¹H NMR spectrum of compound **5c**




Fig. S71. ¹³C NMR spectrum of compound **5c**




Fig. S72. H-H COSY NMR spectrum of compound **5c**




Fig. S73. H-C HSQC NMR spectrum of compound **5c**




Fig. S74. APCI MS spectrum of compound **5d**




Fig. S75. ¹H NMR spectrum of compound **5d**




Fig. S76. High-field part of the ¹³C NMR spectrum of compound **5d**




Fig. S77. Low-field part of the ^{13}C NMR spectrum of compound **5d**




Fig. S78. APCI MS spectrum of compound **5e**




Fig. S79. ^1H NMR spectrum of compound **5e**




Fig. S80. ^{13}C NMR spectrum of compound **5e**




Fig. S81. APCI MS spectrum of compound **5g**




Fig. S82. ¹H NMR spectrum of compound **5g**




Fig. S83. High-field part of the ¹³C NMR spectrum of compound **5g**




Fig. S84. Low-field part of the ^{13}C NMR spectrum of compound **5g**




Fig. S85. H-H COSY NMR spectrum of compound **5g**




Fig. S86. H-C HSQC NMR spectrum of compound **5g**




Fig. S87. APCI MS spectrum of compound **5h** ($[M+Na]^+$)




Fig. S88. ¹H NMR spectrum of compound **5h**




Fig. S89. ^{13}C NMR spectrum of compound 5h




Fig. S90. H-H COSY NMR spectrum of compound 5h




Fig. S91. H-C HSQC NMR spectrum of compound **5h**




Fig. S92. APCI mass spectrum of compound **5i**




Fig. S93. ^1H NMR spectrum of compound **5i**




Fig. S94. ¹³C NMR spectrum of compound 5i




Fig. S95. ¹H NMR spectrum of compound 3j-H




Fig. S96. ¹³C NMR spectrum of compound 3j-H




Fig. S97. Comparison of the selected areas in the ^{13}C NMR spectra of compounds $\text{C}_{60}(\text{OnBu})_5\text{X}$ ($\text{X}=\text{H}$ (1), Br (2) and Cl (3))




Fig. S98. Comparison of the selected areas in the ^{13}C NMR spectra of compounds $\text{C}_{60}(\text{OEt})_5\text{Br}$ (1) and $\text{C}_{60}(\text{OEt})_4\text{O}$ (2)




Fig. S99. ESR spectrum of the reaction mixture $C_{60}Cl_6+DMPO+MeOH+[NBu_4]Br$ in toluene proving radical nature of the investigated reaction




Fig. S100. ESR spectrum of the reaction mixture $C_{60}Cl_6+DMPO+MeOH+NEt_3$ in toluene proving radical nature of the investigated reaction




Fig. S101. ESR spectrum of the reaction mixture $C_{60}Cl_6+DMPO+MeOH+[NBu_4]I$ in toluene proving radical nature of the investigated reaction